Rising Escitalopram Use in British Columbia: Is it Rational and Evidence-Informed?

Plain Language Summary TitleCitalopram vs. Escitalopram for major depression: No Real Difference in Efficacy or Safety, Just Higher Cost.Plain Language SummaryBackground:Citalopram is an antidepressant. Escitalopram is a closely related drug-basically a slightly modified version of citalopram-that drug companies promote as being safer, more effective, and faster acting. In Canada, escitalopram costs about twice as much as citalopram. We wanted to know how these two drugs are actually used in British Columbia and whether escitalopram really works better or is any safer.What We Did:We looked at prescription records for the nine most common antidepressants in BC between 2005 and 2024. We also reviewed all the studies that directly compared citalopram with escitalopram. We focused on whether any differences were large enough to matter to patients, whether study results were reliable, and whether studies had problems such as bias or conflicts of interest.What We Found:By 2013, escitalopram had become the most prescribed antidepressant in BC, while citalopram use dropped. We found 16 studies that compared the two drugs. Many had problems such as missing data, selective reporting, or funding from the drug manufacturer. None of the studies showed meaningful differences in effectiveness. Claims that escitalopram works faster were weak and inconsistent. Side effects were essentially the same, including risks for heart rhythm changes (QT prolongation).

Authors

Institutions

Publication Details

Journal
The Canadian Journal of Psychiatry
Published
2025-12-26
DOI
https://doi.org/10.1177/07067437251405975
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rising Escitalopram Use in British Columbia: Is it Rational and Evidence-Informed?

Aaron M Tejani, Thomas L. Perry, Dionzie Ong, Simroop Ladhar et al.
The Canadian Journal of Psychiatry
Treatment of Major Depression
article

Rising Escitalopram Use in British Columbia: Is it Rational and Evidence-Informed?

Aaron M Tejani, Thomas L. Perry, Dionzie Ong, Simroop Ladhar, Greg Carney, Wade Thompson, Doug Salzwedel
article en

Abstract

Plain Language Summary TitleCitalopram vs. Escitalopram for major depression: No Real Difference in Efficacy or Safety, Just Higher Cost.Plain Language SummaryBackground:Citalopram is an antidepressant. Escitalopram is a closely related drug-basically a slightly modified version of citalopram-that drug companies promote as being safer, more effective, and faster acting. In Canada, escitalopram costs about twice as much as citalopram. We wanted to know how these two drugs are actually used in British Columbia and whether escitalopram really works better or is any safer.What We Did:We looked at prescription records for the nine most common antidepressants in BC between 2005 and 2024. We also reviewed all the studies that directly compared citalopram with escitalopram. We focused on whether any differences were large enough to matter to patients, whether study results were reliable, and whether studies had problems such as bias or conflicts of interest.What We Found:By 2013, escitalopram had become the most prescribed antidepressant in BC, while citalopram use dropped. We found 16 studies that compared the two drugs. Many had problems such as missing data, selective reporting, or funding from the drug manufacturer. None of the studies showed meaningful differences in effectiveness. Claims that escitalopram works faster were weak and inconsistent. Side effects were essentially the same, including risks for heart rhythm changes (QT prolongation).

The Canadian Journal of Psychiatry
University of British Columbia (CA), Fraser Health (CA)
Openalex Percentile: Top 30%
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.